Gyre Therapeutics (GYRE) Interest & Investment Income (2010 - 2023)
Gyre Therapeutics (GYRE) reported Interest & Investment Income of $47000.0 for Q3 2023, down 83.33% year-over-year from $282000.0 in Q3 2022, and down 35.62% on a QoQ basis from $73000.0 in Q2 2023.
Gyre Therapeutics (GYRE) has 14 years of Interest & Investment Income data on file, last reported at $47000.0 in Q3 2023.
- Quarterly Interest & Investment Income fell 83.33% year-over-year to $47000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $384000.0 (down 30.56% YoY) and the FY2022 annual result came in at $717000.0, up 1738.46% from the prior year.
- Interest & Investment Income fell to $47000.0 in Q3 2023 per GYRE's latest filing, from $73000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $631000.0 in Q1 2019 and bottomed at -$634000.0 in Q4 2020.
- The 5-year median for Interest & Investment Income is $102000.0 (2022), against an average of $158052.6.
- The widest annual swing landed in 2020, when Interest & Investment Income sank 249.88%; it then soared 4100.0% in 2022.
- Tracing GYRE's Interest & Investment Income over 5 years: stood at $423000.0 in 2019, then slumped by 249.88% to -$634000.0 in 2020, then soared by 100.63% to $4000.0 in 2021, then soared by 4100.0% to $168000.0 in 2022, then sank by 72.02% to $47000.0 in 2023.
- Per Business Quant, the three latest GYRE Interest & Investment Income figures stand at $47000.0 (Q3 2023), $73000.0 (Q2 2023), and $96000.0 (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 47,000.00 |
| Jun 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 96,000.00 |
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 282,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 11,000.00 |
| Mar 31, 2021 | 17,000.00 |
| Dec 31, 2020 | -634,000.00 |
| Sep 30, 2020 | 74,000.00 |
| Jun 30, 2020 | 113,000.00 |
| Mar 31, 2020 | 334,000.00 |
| Dec 31, 2019 | 423,000.00 |
| Sep 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 601,000.00 |
| Mar 31, 2019 | 631,000.00 |
| Dec 31, 2018 | -1.54 Mn |
| Sep 30, 2018 | 652,000.00 |
| Jun 30, 2018 | 602,000.00 |
| Mar 31, 2018 | 1.64 Mn |
| Dec 31, 2017 | -135,000.00 |
| Sep 30, 2017 | 85,000.00 |
| Jun 30, 2017 | 53,000.00 |
| Mar 31, 2017 | 33,000.00 |
| Dec 31, 2016 | 1.47 Mn |
| Sep 30, 2016 | 941,000.00 |
| Jun 30, 2016 | 82,000.00 |
| Mar 31, 2016 | 980,000.00 |
| Dec 31, 2015 | -446,000.00 |
| Sep 30, 2015 | 273,000.00 |
| Jun 30, 2015 | 516,000.00 |
| Mar 31, 2015 | 174,000.00 |
| Dec 31, 2014 | 497,000.00 |
| Sep 30, 2014 | 136,000.00 |
| Jun 30, 2014 | 154,000.00 |
| Mar 31, 2014 | 178,000.00 |
| Dec 31, 2013 | -458,000.00 |
| Sep 30, 2013 | 257,000.00 |
| Jun 30, 2013 | 131,000.00 |
| Mar 31, 2013 | 224,000.00 |
| Dec 31, 2012 | 252,000.00 |
| Sep 30, 2012 | 239,000.00 |
| Jun 30, 2012 | 280,000.00 |
| Mar 31, 2012 | 299,000.00 |
| Dec 31, 2011 | 373,000.00 |
| Sep 30, 2011 | 316,000.00 |
| Jun 30, 2011 | 343,000.00 |
| Mar 31, 2011 | 316,000.00 |
| Dec 31, 2010 | 363,000.00 |
| Sep 30, 2010 | 360,000.00 |
| Jun 30, 2010 | 366,000.00 |